EUVIMEDEUVIMED entdecken
Crossref

Real World Hospitalizations in US Veterans Treated for Metastatic Prostate Cancer with Combination Therapy

Kara Ingram, Robert Wilson, Jason M Doherty, Daniel B Eaton, Sumrah Khan, Martin W Schoen

Clinical Genitourinary Cancer · 2026-02 · 24 (1) · 102469

DOI: 10.1016/j.clgc.2025.102469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genitourinary Cancer, 2026-02. Verfasst von Kara Ingram und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis MO. Electronic address: kara.ingram@health.slu.edu. Hauptthemen laut MEDLINE: Hospitalization, Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Androgen Antagonists. Die Arbeit nennt 22 Literaturangaben. Gefördert von: CSRD VA, Saint Louis University, Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Treatment of metastatic hormone sensitive prostate cancer (mHSPC) has traditionally included combination therapy of androgen deprivation therapy (ADT) with docetaxel or an androgen receptor pathway inhibitor (ARPI). There are no comparative studies to compare the real-world hospitalization rates and adverse events (AEs). MATERIAL AND METHODS: A nationwide retrospective study of 1549 US veterans was conducted to compare treatment with ADT+docetaxel (n = 500) versus ADT+ARPI (n = 1049) between 2013 and 2021. Hospitalizations were determined 1 year before and after treatment. Baseline cohort characteristics and incidence rate differences of adverse events were then compared in the year prior to treatment with the year after. RESULTS: In patients who received ADT+docetaxel, hospitalizations increased by 245%, and ADT+ARPI hospitalizations increased by 125% (P < .001). The docetaxel cohort was younger and had fewer comorbidities (median age 66.8 vs. 73.4 years; CCI 1 vs. 2). Docetaxel had higher rates of hospitalizations due to digestive (+ 600%, P < .001) and respiratory complications (+ 157%, P = .04). The ARPI cohort had increased hospitalizations due to respiratory (+ 243%, P < .001), endocrine/metabolic (+ 80%, P = .002), and circulatory complications (+ 64%, P = .009). The ARPI cohort had a decrease in acute renal failure admissions (-24%, P = .401). DISCUSSION AND CONCLUSIONS: Overall, in the real-world setting, the 2 therapy regimens have distinct hospitalization risks and AEs. Patients with respiratory and gastrointestinal comorbidities may be at higher risk when receiving treatment with docetaxel. Alternatively, older and frailer patients who are susceptible to infections and metabolic complications may be at increased risk with ARPIs. These findings may aid physicians in determining the optimal, individualized therapy to mitigate adverse outcomes in patients with mHSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationProstatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAndrogen AntagonistsAndrogen Receptor AntagonistsHumansMaleAgedRetrospective StudiesVeteransDocetaxelMiddle AgedUnited StatesAged, 80 and overNeoplasm Metastasis

Stichwörter der Autor:innen

AbirateroneDocetaxelEnzalutamideHospitalizationMetastatic Prostate Cancer

Substanzen

DocetaxelAndrogen AntagonistsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis MO. Electronic address: kara.ingram@health.slu.edu.
  • Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis MO.
  • Advanced Health Data (AHEAD) Research Institute, Saint Louis University School of Medicine, St. Louis, MO.
  • Medicine Service, VA St. Louis Medical Center, St. Louis, MO.
  • Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis MO; Medicine Service, VA St. Louis Medical Center, St. Louis, MO.

Förderung

  • CSRD VA
  • Saint Louis University
  • Astellas Pharma
  • Prostate Cancer Foundation

Zitieren

APA

Ingram, K., Wilson, R., Doherty, J. M., Eaton, D. B., Khan, S., & Schoen, M. W. (2026). Real World Hospitalizations in US Veterans Treated for Metastatic Prostate Cancer with Combination Therapy. Clinical Genitourinary Cancer, 24(1), 102469. https://doi.org/10.1016/j.clgc.2025.102469

Vancouver

Ingram K, Wilson R, Doherty JM, Eaton DB, Khan S, Schoen MW. Real World Hospitalizations in US Veterans Treated for Metastatic Prostate Cancer with Combination Therapy. Clinical Genitourinary Cancer. 2026;24(1):102469. doi:10.1016/j.clgc.2025.102469

BibTeX
@article{Ingram2026,
  author = {Ingram, Kara and Wilson, Robert and Doherty, Jason M and Eaton, Daniel B and Khan, Sumrah and Schoen, Martin W},
  title = {Real World Hospitalizations in US Veterans Treated for Metastatic Prostate Cancer with Combination Therapy},
  journal = {Clinical Genitourinary Cancer},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {102469},
  doi = {10.1016/j.clgc.2025.102469}
}
Kostenlos starten →